Updated linvoseltamab (bcmaxcd3) data from pivotal trial demonstrates early, deep and durable responses in patients with heavily pre-treated multiple myeloma

71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at asco

REGN Ratings Summary

REGN Quant Ranking